Pralatrexate, a new hope for aggressive T-cell lymphomas?
Clin. transl. oncol. (Print)
; 11(4): 215-220, abr. 2009. tab
Article
de En
| IBECS
| ID: ibc-123605
Bibliothèque responsable:
ES1.1
Localisation: BNCS
ABSTRACT
Aggressive T-cell lymphomas represent a particularly poor-prognosis subgroup of lymphomas. This is especially true for patients with recurrent or refractory disease who typically have a limited response to salvage therapy and an extremely poor overall survival. There is thus a strong need to develop potentially active drugs for these malignancies. Pralatrexate is a novel antifolate designed to have high affinity for the reduced folate carrier type 1. Preclinical and clinical studies have demonstrated that pralatrexate has significant activity against T-cell lymphomas.The dose-limiting toxicity for pralatrexate is mucositis,which could be abrogated with folic acid and vitamin B12 supplementation. Pralatrexate is now being evaluated in phase II clinical trials for the treatment of peripheral T-cell lymphoma, and in a phase I/II trial in combination with gemcitabine for the treatment of non-Hodgkin's lymphoma. Because of the limited therapies available for aggressive T-cell lymphoma, pralatrexate could secure a niche for the treatment of this condition, provided on going clinical trials and future phase III trials confirm the efficacy of the drug (AU)
Recherche sur Google
Collection:
06-national
/
ES
Base de données:
IBECS
Sujet principal:
Essais cliniques comme sujet
/
Lymphome T
/
Antifoliques
/
Aminoptérine
/
Antinéoplasiques
Type d'étude:
Prognostic_studies
Limites:
Animals
/
Female
/
Humans
/
Male
Langue:
En
Journal:
Clin. transl. oncol. (Print)
Année:
2009
Type de document:
Article